



Neurocrine Biosciences Statement in Response to COVID-19

March 18, 2020

As we continue to monitor COVID-19 developments, at Neurocrine Biosciences we are committed to the safety, health and well-being of our patients, customers and employees. To healthcare providers and their patients with tardive dyskinesia, we do not anticipate any disruption in our ability to supply INGREZZA® (valbenazine). Be assured, we remain focused on our mission to discover, develop and deliver important medicines to treat patients with neurological, endocrine, and psychiatric disorders.